Jeffrey A. Knauf

Cleveland Clinic — United States

Medicine · Health Sciences

50h-index12.9kcitations365works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Thyroid Cancer Diagnosis and Treatment(143), Nutrition, Genetics, and Disease(76), Cancer-related Molecular Pathways(58), Chromatin Remodeling and Cancer(35), Cancer Mechanisms and Therapy(29)

Publications365 total

Supplementary Table 6 from Telomerase Upregulation Induces Progression of Mouse Braf<sup>V600E</sup>-Driven Thyroid Cancers and Triggers Nontelomeric Effects
2025Open Access
Supplementary Table and Figure Legends from Telomerase Upregulation Induces Progression of Mouse Braf<sup>V600E</sup>-Driven Thyroid Cancers and Triggers Nontelomeric Effects
2025Open Access
Supplementary Figure 4 from Telomerase Upregulation Induces Progression of Mouse Braf<sup>V600E</sup>-Driven Thyroid Cancers and Triggers Nontelomeric Effects
2025Open Access
Supplementary Table 4 from Telomerase Upregulation Induces Progression of Mouse Braf<sup>V600E</sup>-Driven Thyroid Cancers and Triggers Nontelomeric Effects
2025Open Access
Supplementary Table 2 from Telomerase Upregulation Induces Progression of Mouse Braf<sup>V600E</sup>-Driven Thyroid Cancers and Triggers Nontelomeric Effects
2025Open Access
Supplementary Table 7 from Telomerase Upregulation Induces Progression of Mouse Braf<sup>V600E</sup>-Driven Thyroid Cancers and Triggers Nontelomeric Effects
2025Open Access
Supplementary Table 5 from Telomerase Upregulation Induces Progression of Mouse Braf<sup>V600E</sup>-Driven Thyroid Cancers and Triggers Nontelomeric Effects
2025Open Access
Supplementary Figure 1 from Telomerase Upregulation Induces Progression of Mouse Braf<sup>V600E</sup>-Driven Thyroid Cancers and Triggers Nontelomeric Effects
2025Open Access
Supplementary Table 1 from Telomerase Upregulation Induces Progression of Mouse Braf<sup>V600E</sup>-Driven Thyroid Cancers and Triggers Nontelomeric Effects
2025Open Access
Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025Open Access
EWSR1 fusion neoantigen vaccine for the treatment of recurrent Ewing sarcoma 9402
The Journal of Immunology·2025Open Access
page 1 of 19Next →

Frequent Co-authors

James A. Fagin(49), Ronald Ghossein(18), Julio C. Ricarte‐Filho(7), Yuri E. Nikiforov(6), Iñigo Landa(6), Norisato Mitsutake(6), Gnana P. Krishnamoorthy(5), Ian Ganly(5), Mabel Ryder(5), R. Michael Tuttle(5), Neal Rosen(5), Marina N. Nikiforova(4), Snjezana Doğan(4), Bin Xu(4), Massimo Santoro(4), Samuel Refetoff(4), María E.R. García-Rendueles(4), Venkatraman Seshan(4), Alan L. Ho(4), Mahesh Saqcena(4)